{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T20:45:03Z","timestamp":1768941903505,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101119","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T11:46:23Z","timestamp":1691667983000},"page":"101119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?"],"prefix":"10.1016","volume":"62","author":[{"given":"D.","family":"Santagata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Donadini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.blre.2023.101119_bb0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1212\/WNL.0b013e3182a2cc15","article-title":"Association of atrial fibrillation with mortality and disability after ischemic stroke","volume":"81","author":"McGrath","year":"2013","journal-title":"Neurology"},{"issue":"40","key":"10.1016\/j.blre.2023.101119_bb0010","first-page":"4194","volume":"42","author":"Hindricks","year":"2020","journal-title":"Erratum in: Eur heart J"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.blre.2023.101119_bb0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann InternMed"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0025","first-page":"CD001927","article-title":"Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks","volume":"2005","author":"Aguilar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"9526","key":"10.1016\/j.blre.2023.101119_bb0030","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2023.101119_bb0035","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","volume":"8","author":"Bruins Slot","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"9921","key":"10.1016\/j.blre.2023.101119_bb0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2023.101119_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2018.05.022","article-title":"Dabigatran, rivaroxabanandapixaban vs. high TTR warfarin in atrial fibrillation","volume":"167","author":"Sj\u00e4lander","year":"2018","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","article-title":"Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials","volume":"38","author":"Amin","year":"2014","journal-title":"J ThrombThrombolysis"},{"issue":"11","key":"10.1016\/j.blre.2023.101119_bb0055","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"INVICTUS Investigators. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0065","article-title":"Incidenceof atrial fibrillation in largevessel occlusion and large embolic stroke of undetermined source","volume":"15","author":"Seachrist","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.blre.2023.101119_bb0070","doi-asserted-by":"crossref","first-page":"120610","DOI":"10.1016\/j.jns.2023.120610","article-title":"Association of non-sustained atrial tachycardia and its duration in 24-h Holter monitoring with embolic stroke of unknown source","volume":"447","author":"Choi","year":"2023","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0075","first-page":"187","article-title":"Are factor Xa inhibitors efficacious for ischemic stroke prevention in patients without atrial fibrillation? Evidence from randomized clinical trials","volume":"39","author":"Hart","year":"2023","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/23969873221076971","article-title":"Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis","volume":"7","author":"Hariharan","year":"2022","journal-title":"Eur Stroke J"},{"issue":"18","key":"10.1016\/j.blre.2023.101119_bb0085","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","article-title":"Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents","volume":"121","author":"Paikin","year":"2010","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jjcc.2018.09.001","article-title":"Triple therapy: a review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"73","author":"Saito","year":"2019","journal-title":"J Cardiol"},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0095","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvaa258","article-title":"Pathophysiology of atrial fibrillation and chronic kidney disease","volume":"117","author":"Ding","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"23","key":"10.1016\/j.blre.2023.101119_bb0100","first-page":"2262","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012 Aug 16;367(7):625\u201335. doi: 10.1056\/NEJMoa1105594","volume":"367","author":"Olesen","year":"2012","journal-title":"Erratum in: N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101119_bb0105","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s12325-021-01769-9","article-title":"Unmet clinical needs in elderly patients receiving direct oral anticoagulants for stroke prevention in non-valvular atrial fibrillation","volume":"38","author":"Botto","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.blre.2023.101119_bb0110","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101119_bb0115","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban VS warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101119_bb0120","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation, and innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J ThrombHaemost"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0130","first-page":"331","article-title":"The contact pathway and sepsis","volume":"3","author":"Raghunathan","year":"2019","journal-title":"Res PractThrombHaemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/asheducation-2014.1.60","article-title":"Recent insights into the role of the contact pathway in thrombo-inflammatory disorders","volume":"2014","author":"van Montfoort","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.blre.2023.101119_bb0140","first-page":"437","article-title":"Factor XI\/XIa inhibition: the arsenal in development for a new therapeutic target in cardio- and cerebrovascular disease","volume":"9","author":"Badimon","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12185-016-2132-x","article-title":"The initiation and effects of plasma contact activation: an overview","volume":"105","author":"Lin","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2023.101119_bb0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"Anupdateonfactor XI structureandfunction","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jth.13194","article-title":"The contact activation and kallikrein\/kinin systems: pathophysiologic and physiologic activities","volume":"14","author":"Schmaier","year":"2016","journal-title":"J ThrombHaemost"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2023.101119_bb0160","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(16)30354-1","article-title":"The hemostatic role of factor XI","volume":"141","author":"Puy","year":"2016","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0165","first-page":"331","article-title":"Intrinsic pathway of Coagulation and Thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"ArteriosclerThrombVascBiol."},{"issue":"6","key":"10.1016\/j.blre.2023.101119_bb0170","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jtha.2023.02.031","article-title":"Predictive value for increased activated factor XI activity in acute venous thromboembolism","volume":"21","author":"Nagy","year":"2023","journal-title":"J ThrombHaemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0175","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J ThrombHaemost"},{"issue":"9","key":"10.1016\/j.blre.2023.101119_bb0180","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jth.13766","article-title":"Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein","volume":"15","author":"Ay","year":"2017","journal-title":"J ThrombHaemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0185","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/jth.15236","article-title":"Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"19","author":"Ngo","year":"2021","journal-title":"J ThrombHaemost"},{"issue":"11","key":"10.1016\/j.blre.2023.101119_bb0190","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.blre.2023.101119_bb0195","first-page":"2489","article-title":"Activation of clotting factors XI and IX in patients with acute myocardial infarction","volume":"20","author":"Minnema","year":"2000","journal-title":"ArteriosclerThrombVascBiol."},{"issue":"6","key":"10.1016\/j.blre.2023.101119_bb0200","first-page":"883","article-title":"Role of factor XIa and plasma Kallikrein in arterial and venous Thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"ThrombHaemost."},{"issue":"5","key":"10.1016\/j.blre.2023.101119_bb0205","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.5114\/aoms.2015.54791","article-title":"Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke","volume":"12","author":"Kusak","year":"2016","journal-title":"Arch Med Sci"},{"issue":"8","key":"10.1016\/j.blre.2023.101119_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019644","article-title":"Genetically proxied inhibition of coagulation factors and risk of cardiovascular disease: a mendelian randomization study","volume":"10","author":"Yuan","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2023.101119_bb0215","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front CardiovascMed"},{"issue":"5","key":"10.1016\/j.blre.2023.101119_bb0220","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jtha.2023.02.008","article-title":"Recommendation on the nomenclature for anticoagulants: updated communication from the international society on thrombosis and haemostasis scientific and standardization commitee on the control of anticoagulation","volume":"21","author":"Barnes","year":"2023","journal-title":"J ThrombHaemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0225","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie."},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0230","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J ThrombHaemost"},{"issue":"10","key":"10.1016\/j.blre.2023.101119_bb0235","first-page":"2448","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J ThrombHaemost. 2022 Jun;20(6):1400\u20131411. doi: 10.1111\/jth.15700. Epub 2022 Mar 25","volume":"20","author":"Heitmeier","year":"2022","journal-title":"Erratum in: J ThrombHaemost"},{"issue":"7","key":"10.1016\/j.blre.2023.101119_bb0240","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0245","first-page":"1030","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J ThrombHaemost. 2022 Feb;20(2):399\u2013408. doi: 10.1111\/jth.15588. Epub 2021 Nov 24","volume":"20","author":"Wong","year":"2022","journal-title":"Erratum in: J ThrombHaemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0250","first-page":"1085","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022 Feb;15(2):330\u2013342. doi: 10.1111\/cts.13148. Epub 2021 Sep 24","volume":"15","author":"Perera","year":"2022","journal-title":"Erratum in: Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0255","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0260","doi-asserted-by":"crossref","first-page":"22239","DOI":"10.1038\/s41598-022-25936-2","article-title":"Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0265","first-page":"407","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor XIa inhibitor","volume":"11","author":"Perera","year":"2022","journal-title":"CardiolTher."},{"issue":"10333","key":"10.1016\/j.blre.2023.101119_bb0270","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Patel MR; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.blre.2023.101119_bb0275","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J ThrombHaemost"},{"issue":"11","key":"10.1016\/j.blre.2023.101119_bb0280","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J ThrombHaemost"},{"issue":"23","key":"10.1016\/j.blre.2023.101119_bb0285","volume":"146","author":"Rao","year":"2022","journal-title":"Erratum in: Circulation"},{"issue":"23","key":"10.1016\/j.blre.2023.101119_bb0290","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation."},{"issue":"10357","key":"10.1016\/j.blre.2023.101119_bb0295","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.blre.2023.101119_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106742","article-title":"Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize Management of Acute Thromboembolic events for secondary stroke prevention","volume":"31","author":"Sharma","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.blre.2023.101119_bb0305","series-title":"Oral presentation at the European Society of Cardiology Congress (ESC 2022). Barcelona, Spain, August 28","author":"Sharma","year":"2022"},{"issue":"6","key":"10.1016\/j.blre.2023.101119_bb0310","first-page":"576","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"ThrombHaemost."},{"key":"10.1016\/j.blre.2023.101119_bb0315","article-title":"Blood coagulation and beyond: position paper from the fourth maastricht consensus conference on thrombosis","author":"Akbulut","year":"2023","journal-title":"ThrombHaemost"},{"issue":"23","key":"10.1016\/j.blre.2023.101119_bb0320","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101119_bb0325","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"ANT-005 TKA Investigators. Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101119_bb0330","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0335","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA."},{"issue":"12","key":"10.1016\/j.blre.2023.101119_bb0340","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J ThrombHaemost"},{"key":"10.1016\/j.blre.2023.101119_bb0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V29.3.331.331","article-title":"Differential consumption of coagulation factors resulting from activation of the extrinsic (tissue thromboplastin) or the intrinsic (foreign surface contact) pathways","volume":"29","author":"Nossel","year":"1967","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101119_bb0350","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 scientific sessions sol Sherry distinguished lecture in thrombosis: factor XI as a target for new anticoagulants","volume":"38","author":"Weitz","year":"2018","journal-title":"ArteriosclerThrombVasc Biol"},{"issue":"8","key":"10.1016\/j.blre.2023.101119_bb0355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.blre.2023.101119_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-023-00872-4","article-title":"Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale","author":"Gigante","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101119_bb0365","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J ThrombHaemost"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:32:39Z","timestamp":1759437159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":73,"alternative-id":["S0268960X23000802"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101119","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101119"}}